SGHT: Bull Flag detected on 3 Sep 2026

SGHT forms a bull flag pattern with a 79.0 overall quality score anchored by strong structure (15.0/15) and solid breakout potential (12.0/13). The flag consolidates between support at $7.82 and resistance at $8.85, with the stock currently at $8.42. Volume remains modest at 269,379 shares (0.93 relative volume), which tempers the setup slightly. RSI at 68.4 approaches overbought territory. The pattern sits within the upper range of its 20-day Bollinger Bands (0.672 position), suggesting price momentum may face friction.

Sight Sciences reported Q2 2026 revenue of $23.4 million (20% YoY growth) on August 5, 2026, while raising full-year 2026 revenue guidance and reducing adjusted operating expense guidance. Interventional Glaucoma revenue grew 8% to $20.7 million, indicating sustained momentum in the core business. Interventional Dry Eye revenue surged 244% YoY in Q1 2026 to $1.4 million, demonstrating early traction in the company's secondary growth driver. This triple-beat earnings cycle, combined with forward guidance raises, created positive momentum into late August. Management is scheduled to present at the Morgan Stanley Global Healthcare Conference on September 15, 2026, offering potential near-term visibility. The bull flag forms just weeks after this fundamental catalyst, suggesting institutional positioning into the conference presentation.

A successful breakout would clear resistance at $8.85 with volume confirmation above the 289k-share 20-day average, targeting the conservative measured move of $8.70. Given the 70.66% win probability and moderate consolidation structure, the pattern suggests controlled upside over 1–3 weeks. Key invalidation occurs at support $7.82; a close below this level would negate the setup and suggest capitulation. The bull flag's moderate volume (9.0/12) means breakout conviction requires visible volume expansion; a breakout on declining volume would reduce reliability and likely fail to extend toward the measured target.

Recent insider activity showed net selling, raising questions about management confidence at current valuations. The most recent analyst rating is Hold with a $4.35 price target, significantly below the current $8.42 price, suggesting structural skepticism among coverage analysts despite recent earnings beats. RSI at 68.4 signals near-overbought conditions, leaving minimal room for momentum before mean reversion. The broader market regime is bearish (-0.23 score), creating headwinds despite the healthcare sector's bullish regime. No next earnings date is imminent (prior Q2 report was August 5), reducing near-term fundamental catalysts beyond the September 15 conference; any post-event disappointment could trigger a flush. The stock's low beta (0.36) provides some defensive protection but limits upside participation in positive market rotations.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.